Digoxin therapeutic drug monitoring: An audit and review

New Zealand Medical Journal

Volumn 116, Issue 1187, 2003, Pages

  Sidwell, Andrew I ^a   Barclay, Murray L ^a   Begg, Evan J ^a   Moore, Grant A ^b  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b CANTERBURY HEALTH LABORATORIES   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; ANTIARRHYTHMIC AGENT; CARDIOTONIC AGENT;

BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MONITORING; DRUG WITHDRAWAL; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MEASUREMENT; MEDICAL AUDIT; MEDICAL DECISION MAKING; MEDICAL EDUCATION; MEDICAL RECORD; REVIEW; SIDE EFFECT; STEADY STATE; TIME; TREATMENT FAILURE; ARTICLE; BLOOD; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; NEW ZEALAND; STATISTICS;

ANTI-ARRHYTHMIA AGENTS; CARDIOTONIC AGENTS; DIGOXIN; DRUG MONITORING; HEART FAILURE, CONGESTIVE; HUMANS; MEDICAL AUDIT; NEW ZEALAND; PHYSICIAN'S PRACTICE PATTERNS;

EID: 17944389091     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Smith TW, Haber E. Digoxin Intoxication: the relationship of clinical presentation to serum digoxin concentration. J Clin Invest 1970;49:2377-86.
2. Beller GA, Smith TW, Abelmann WH, et al. Digitalis intoxication. A prospective clinical study with serum level correlations. N Engl J Med 1971;284:989-97.
3. Duhme DW, Greenblatt DJ, Koch-Weser J. Reduction of digoxin toxicity associated with measurement of serum levels. A report from the Boston Collaborative Drug Surveillance Program. Ann Intern Med 1974;80:516-9.
4. Williamson KM, Thrasher KA, Fulton KB, et al. Digoxin toxicity: an evaluation in current clinical practice. Arch Intern Med 1998;158:2444-9.
5. Makela EH, Davis SK, Piveral K, et al. Effect of data collection method on results of serum digoxin concentration audit. Am J Hosp Pharm 1988;45:126-30.
6. Mayan H, Bloom E, Hoffman A. Use of digoxin monitoring in a hospital setting as an essential tool in optimizing therapy. J Pharm Technol 2002;18:133-6.
7. Masuhara JE, Lalonde RL. Serum digoxin concentrations in atrial fibrillation: a review. Drug Intell Clin Pharm 1982;16:543-61.
8. Adams KF Jr, Gheorghiade M, Uretsky BF, et al. Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol 2002;39:946-53.
9. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration andoutcomes in patients with heart failure. JAMA 2003;289:871-8.
10. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002;347:1403-11.
11. Fraser GL, Wennberg DE, Dickens JD Jr, Lambrew CT. Changing physician behaviour in ordering digoxin assays. Ann Pharmacother 1996;30:449-54.